Please login to the form below

Not currently logged in
Email:
Password:

EMA recommends electronic submissions for drug marketing authorisation

Follows successful four-month pilot

The European Medicines Agency (EMA) has recommend companies use its electronic form to submit drug marketing authorisation applications following a successful pilot.

Firms are encouraged to download and submit interactive PDF forms to apply for initial marketing authorisations, variations or renewals for human and veterinary medicines to “simplify and speed up the application process”.

According to the EMA, benefits of this system include:

  • Improvements to the quality and consistency of data
  • Access to data in Extensible Markup Language (XML) format
  • Integrating application data with a list of controlled terms.

The pilot has been ongoing since March, 2012, initially involving human medicines before being expanded to veterinary applications.

Plans have been in place since 2003 to move away from a paper-based application process with the launch of the Electronic Common Technical Document (eCTD).

Uptake had previously been limited, due in part to the complexity of the process, but this new more straightforward method appears to have proved popular with pharma companies using them and eCTD looks set to be the standard application process from now on.

The electronic forms are available to downloads from the EMA's eSubmission website, which describes them as an “alternative, convenient, online version of the currently used paper forms”.

Also available on the eSubmission website are user guidance forms about the electronic process and Data Exchange Standards and XML Schema Definitions documents that are intended to allow software developers within other organisations to develop systems to process the electronic application form data and build equivalent systems, if required.

27th July 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics